Moderna (MRNAUS) Stock Overview
A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
MRNAUS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Moderna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$145.55 |
| 52 Week High | US$155.00 |
| 52 Week Low | US$29.43 |
| Beta | 1.11 |
| 1 Month Change | 143.35% |
| 3 Month Change | 205.78% |
| 1 Year Change | 433.35% |
| 3 Year Change | 32.14% |
| 5 Year Change | -65.05% |
| Change since IPO | -2.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRNAUS | PE Biotechs | PE Market | |
|---|---|---|---|
| 7D | 3.7% | 0% | 0% |
| 1Y | 433.3% | 0% | 0% |
Return vs Industry: MRNAUS exceeded the PE Biotechs industry which returned 17.9% over the past year.
Return vs Market: MRNAUS exceeded the PE Market which returned 50% over the past year.
Price Volatility
| MRNAUS volatility | |
|---|---|
| MRNAUS Average Weekly Movement | 42.7% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in PE Market | 0% |
| 10% least volatile stocks in PE Market | 0% |
Stable Share Price: MRNAUS's share price has been volatile over the past 3 months compared to the PE market.
Volatility Over Time: MRNAUS's weekly volatility has increased from 22% to 43% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 4,700 | Stéphane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.
Moderna, Inc. Fundamentals Summary
| MRNAUS fundamental statistics | |
|---|---|
| Market cap | US$57.48b |
| Earnings (TTM) | -US$3.15b |
| Revenue (TTM) | US$2.23b |
Is MRNAUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRNAUS income statement (TTM) | |
|---|---|
| Revenue | US$2.23b |
| Cost of Revenue | US$3.70b |
| Gross Profit | -US$1.47b |
| Other Expenses | US$1.68b |
| Earnings | -US$3.15b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.89 |
| Gross Margin | -66.02% |
| Net Profit Margin | -141.43% |
| Debt/Equity Ratio | 8.7% |
How did MRNAUS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/12 22:58 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Moderna, Inc. is covered by 42 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Eliana Merle | Barclays |
| Huidong Wang | Barclays |